Loading cancer entity…
Loading cancer entity…
Clinical trials
47 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (5)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06239272 | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | recruiting | Phase 1 / Phase 2 | 139 | St. Jude Children's Research HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04332874 | A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 |
| Apr 23, 2026 |
| clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07169344 | Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma(PROSARC-1) | recruiting | Phase 2 | 110 | Oslo University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07173972 | Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.(PROSARC-2) | recruiting | Phase 2 | 40 | Oslo University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06849986 | IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)(TAIS) | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT03899792 | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors(LIBRETTO-121) | active not recruiting | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 11 | Jan 6, 2026 | clinicaltrials |
| NCT03834961 | Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia | active not recruiting | Phase 2 | 33 | Children's Oncology GroupNETWORK | 2 | Dec 2, 2025 | clinicaltrials |
| NCT06277154 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 148 | HRYZ Biotech Co.INDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Aug 3, 2026source: clinicaltrials